NCT06819293View on ClinicalTrials.gov

IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

December 7, 2027

Study Completion Date

December 7, 2027

Conditions
Advanced Clear Renal Cell CarcinomaAdult
Interventions
BIOLOGICAL

IB-T101 injection

IB-T101 injection to treat advanced clear renal cell carcinoma

Trial Locations (1)

Unknown

RECRUITING

Tongji hospital, Huazhong University of Science and Technology, Wuhan

Sponsors

Lead Sponsor

Grit Biotechnology
All Listed Sponsors
lead

Grit Biotechnology

INDUSTRY

NCT06819293 - IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter